Brussels, 16 January 2023 – EuropaBio is pleased to announce that SwiftPharma has joined the association as a Corporate SME.

SwiftPharma is a biotech start-up, focused on the Research & Development of next generation biologics. It is specialised in plant-made biologics, using molecular farming and a data-driven approach to design and produce next-generation proteins. According to SwiftPharma, their plants produce vaccines, antibodies, cytokines, enzymes and other high-value, animal-free proteins that re-define safety and sustainability.

As a member of EuropaBio, SwiftPharma aims to be actively involved across sectors and a valued SME contributor to the recently launched EuropaBio Biomanufacturing Platform.

EuropaBio Director-General Dr. Claire Skentelbery commented “next generation biomanufacturing by SMEs is exactly the route that Europe must take and SwiftPharma demonstrates how we can be competitive, agile and resilient across sectors. We are delighted to bring the voice of SwiftPharma into our advocacy for biotechnology in Europe.”

Jeroen Hofenk, SwiftPharma Founder and CSO added: “We are very excited about being included into the EuropaBio family. Our company mission closely aligns with that of EuropaBio by focusing on technologies that improve the diagnosing, treatment, prevention, and ultimately the curing of diseases. Our technology has the potential to improve existing products by making them safer, less expensive, and with unlimited scalability. Just as importantly the SwiftPharma platform provides opportunities for new products and innovation that can have a major impact in a multitude of sectors”.